The Scientific Team at Palleon Pharmaceuticals conducts cutting-edge research and development focused on Glyco-Immune Checkpoint inhibitors to combat cancer. This multidisciplinary team, which includes senior scientific advisors and R&D experts, collaborates on preclinical and clinical studies, engages in detailed analytical and formulation development, and contributes to the overall scientific strategy guiding Palleon's innovative treatment solutions.
Carolyn Bertozzi
Co-Founder, Scientific Advisor
James Paulson
Scientific Advisor
Jeffrey Ravetch
Scientific Advisor
Li Peng
Chief Scientific Officer
Paul Crocker
Co-Founder, Scientific Advisor
Peter Murray
Scientific Advisor
Rakesh Dixit
Senior R&D Advisor
Rob Kramer
Senior R&D Advisor
Robert LeBlanc III
Scientist
Stephan von Gunten
Scientific Advisor